| 12 Integration of Target-Based Agents MC Piccirillo, F Falasconi, A Del Giudice, G De Feo, J Bryce, M Iaccarino, ... Breast Cancer in the Post-Genomic Era, 203, 2009 | | 2009 |
| 1207O Bevacizumab+ erlotinib vs erlotinib alone as first-line treatment of pts with EGFR mutated advanced non squamous NSCLC: final analysis of the multicenter, randomized … MC Piccirillo, L Bonanno, MCC Garassino, C Dazzi, L Cavanna, ... Annals of Oncology 32, S950, 2021 | 15 | 2021 |
| 1245 Zoledronic acid and Taxotere (ZANTE) metronomic and sequential administration in patients with hormone refractory prostate cancer (HRPC)–final results of phase I study M Caraglia, A Morabito, M Marra, AM Bochicchio, MC Piccirillo, R Franco, ... EJC Supplements 2 (7), 134, 2009 | 1 | 2009 |
| 167P Chemotherapy-induced neutropenia and treatment efficacy in advanced non-small cell lung cancer (aNSCLC): a pooled analysis of 6 randomized trials P Gargiulo, R Di Liello, L Arenare, C Gridelli, A Morabito, F Ciardiello, ... Journal of Thoracic Oncology 16 (4), S789-S790, 2021 | 1 | 2021 |
| 2034 POSTER Weekly docetaxel vs CMF as adjuvant chemotherapy for elderly breast cancer patients: safety data from the ELDA trial F Nuzzo, F Perrone, V Labonia, C Pacilio, A Gravina, G D'Aiuto, ... EJC Supplements 4 (5), 194, 2007 | 1 | 2007 |
| 5047 Effects on quality of life (QoL) of docetaxel-based weekly chemotherapy in patients with locally advanced (LABC) or metastatic breast cancer (MBC): results of a single … F Nuzzo, F Di Rella, A Morabito, A Gravina, V Labonia, G Landi, C Pacilio, ... EJC Supplements 2 (7), 274-275, 2009 | | 2009 |
| 593P Longitudinal description of clinical trials for the development of cyclin-dependent kinases inhibitors C Cardone, C Schettino, P Gargiulo, L Arenare, S Bevilacqua, ... Annals of Oncology 31, S497-S498, 2020 | | 2020 |
| 8104 POSTER Expanding the role of the clinical research nurse in an Italian cooperative oncology research group J Bryce, MG Catapano, M Falanga, M Connola, C Pisano, A Morabito, ... EJC Supplements 4 (5), 439, 2007 | | 2007 |
| 8185 POSTER Early stopping of 2 clinical trials for futility: an exploratory study of patients' reactions J Bryce, M Connola, MG Chiofalo, C Caraco, K Monaco, M Piccirillo, ... EJC Supplements 4 (5), 462, 2007 | | 2007 |
| A multicenter randomized phase 4 trial comparing sodium picosulphate plus magnesium citrate vs. polyethylene glycol plus ascorbic acid for bowel preparation before colonoscopy … V D’Angelo, MC Piccirillo, M Di Maio, C Gallo, C Bucci, C Civiletti, ... Frontiers in Medicine 9, 1013804, 2022 | | 2022 |
| A multicenter, randomised, phase 3 trial comparing fixed dose versus toxicity-adjusted dose of cisplatin+ etoposide in advanced SCLC patients (pts). The STAD-1 trial G Daniele, A Morabito, A Favaretto, V Filipazzi, A Rossi, V Gebbia, ... Annals of Oncology 26, vi73, 2015 | | 2015 |
| A multicenter, randomised, phase III trial comparing fixed dose versus toxicity-adjusted dose of cisplatin+ etoposide in advanced SCLC patients. The STAD-1 trial. A Morabito, G Daniele, AG Favaretto, V Filipazzi, A Rossi, V Gebbia, ... Journal of Clinical Oncology 33 (15_suppl), 7505-7505, 2015 | 2 | 2015 |
| A multicenter, randomized, phase 3 trial comparing fixed dose versus toxicity-adjusted dose of cisplatin+ etoposide in extensive small-cell lung cancer (SCLC) patients: the … A Morabito, G Daniele, R Costanzo, AG Favaretto, V Filipazzi, A Rossi, ... Lung Cancer 108, 15-21, 2017 | 13 | 2017 |
| A multicentre, randomized phase 3 study on the optimization of the combination of bevacizumab with FOLFOX/OXXEL in the treatment of patients with metastatic colorectal cancer … A Antonio, MC Piccirillo, G Nasti, G Rosati, C Chiara, C Romano, ... Annals of Oncology 27, iv42, 2016 | | 2016 |
| A multicentre, randomized phase 3 study on the optimization of the combination of bevacizumab with mFOLFOX/OXXEL in patients with metastatic colorectal cancer (mCRC) A Avallone, G Nasti, G Rosati, C Carlomagno, C Romano, D Bilancia, ... Annals of Oncology 28, v173-v174, 2017 | | 2017 |
| A phase 2, open label, multicenter, single arm study of tocilizumab on the efficacy and tolerability of tocilizumab in the treatment of patients with COVID-19 pneumonia … P Chiodini, L Arenare, MC Piccirillo, F Perrone, C Gallo Contemporary clinical trials communications 20, 100665, 2020 | 12 | 2020 |
| A qualitative analysis and development of a conceptual model assessing financial toxicity in cancer patients accessing the universal healthcare system S Riva, F Efficace, M Di Maio, J Bryce, L Del Campo, F De Lorenzo, ... Supportive Care in Cancer 29, 3219-3233, 2021 | 15 | 2021 |
| A randomized phase 3 study on the optimization of the combination of bevacizumab with FOLFOX/OXXEL in the treatment of patients with metastatic colorectal cancer-OBELICS … A Avallone, MC Piccirillo, L Aloj, G Nasti, P Delrio, F Izzo, E Di Gennaro, ... BMC cancer 16, 1-10, 2016 | 21 | 2016 |
| Adams R Alavi A Apostolopoulos V Arlen P Arts H M Bareschino, S Basu, S Bonovas, A Cats, A Chang, L Chang, ... | | |
| Addition of bevacizumab to erlotinib as first-line treatment of patients with EGFR-mutated advanced nonsquamous NSCLC: the BEVERLY multicenter randomized phase 3 trial MC Piccirillo, L Bonanno, MC Garassino, G Esposito, C Dazzi, L Cavanna, ... Journal of Thoracic Oncology 17 (9), 1086-1097, 2022 | 36 | 2022 |
